New York, USA – Creative Biolabs, an established leading expert in TCR and CAR-T&NK cell immune therapy development, is committed to providing cost-effective products and services for both academic and industrial clients.
Chimeric Antigen T (CAR-T) cell therapy has emerged as one of the most potent cancer immunotherapies in recent years, showing striking therapeutic effects in a variety of malignancies and diseases, such as hematological tumors, prostate cancers. Based on a comprehensive product system, Creative Biolabs is capable of offering a full list of CAR vector and viral particle products for CAR-T/TCR-T Cell Therapy to help clients with the research of corresponding diseases, including but not limited to:
The human CD19 antigen is a 95 kkDa transmembrane glycoprotein with conserved expression on most B cell tumors, such as acute lymphoblastic leukemias (ALL), chronic lymphocytic leukemias (CLL) and B cell lymphomas. Therefore, CD19 becomes one of the most popular targets widely used for studying lymphoma, leukemia and autoimmune disorders.
Products: Anti-CD19 scFv h(CD28) CARNK, pCDCAR1; Anti-CD19 (Denintuzumab) h(41BB-CD3?) CAR, pCDCAR1; Anti-CD19 (104881) h(41BB-CD3?) CAR, pCDCAR1…
New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a cancer-testis antigen (CTA) re-expressed in many tumors, which can elicit spontaneous humoral and cellular immune responses as well as a restricted expression pattern and is therefore a powerful candidate target for cancer immunotherapy.
Products: Anti-NY-ESO-1 scFv h(CD28) CART, pCDCAR1; Anti-NY-ESO-1 (3E4M5) h(4-1BB-CD3?) CAR, pCDCAR1; Anti-NY-ESO-1 (E978) h(4-1BB-CD3?) CAR, pCDCAR1…
Prostate-specific membrane antigen (PSMA) a zinc metalloenzyme that locates in membranes. Owing to its low expression in prostate tissue and its high expression in prostate cancer and metastases, PSMA is widely used as vectors to transport drug to tumor tissue by PSMA, which enables an accurate treatment of prostate cancer.
Products: Anti-PSMA (CBL-YF023) h(4-1BB-CD3?) CAR, pCDCAR1; Anti-PSMA (MLN591) h(41BB-CD3?) CAR, pCDCAR1; Anti-PSMA (F-2) h(CD28-CD3?) CAR, pCDCAR1…
“We not only provide these popular products for CAR-T therapy. Our scientists also have accumulated deep scientific and regulatory understanding of various drug discovery and development solutions. We aim to support global researchers to shape a novel therapy by our highly customized services and products that reduce risk and accelerate timelines,” said the manager at Creative Biolabs.
With years of experiences in CAR-T field, Creative Biolabs has completed an exclusive platform that covers all steps of a successful CAR-T therapy.
More information can be reached at https://www.creative-biolabs.com/car-t.
About Creative Biolabs
As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, the established leading experts in TCR and CAR-T&NK cell immune therapy development offer the one-stop custom services that cover the entire new drug development pipeline, and an exclusive line of ready-to-use TCR and CAR-T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, a unique unparalleled CAR construction and production platform has been built up for all four CAR generations.